Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome

The multiple myelomas — current concepts in cytogenetic classification and therapy

(2018) Shaji K. Kumar et al.   Nature Reviews Clinical Oncology

Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance

(2018) Robert A. Kyle et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial

(2017) Brian G M Durie et al.   LANCET

Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial

(2017) H Goldschmidt et al.   LEUKEMIA

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma

(2017) Michel Attal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survival

(2017) M Chin et al.   Blood Cancer Journal

Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker

(2017) S S Chavan et al.   Blood Cancer Journal

Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma

(2017) M Binder et al.   Blood Cancer Journal

Progress in Myeloma — A Monoclonal Breakthrough

(2016) S. Vincent Rajkumar et al.   NEW ENGLAND JOURNAL OF MEDICINE

New investigational drugs with single-agent activity in multiple myeloma

(2016) A M Rajan et al.   Blood Cancer Journal

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

(2015) Antonio Palumbo et al.   JOURNAL OF CLINICAL ONCOLOGY

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

(2014) S Vincent Rajkumar et al.   LANCET ONCOLOGY

Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients

(2013) S K Kumar et al.   LEUKEMIA

Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma

(2013) A J Greenberg et al.   LEUKEMIA

Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma

(2013) S V Rajkumar et al.   LEUKEMIA

Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013

(2013) Joseph R. Mikhael et al.   MAYO CLINIC PROCEEDINGS

Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics

(2012) S. Kumar et al.   BLOOD

Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG)

(2009) E Kastritis et al.   LEUKEMIA